Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease.
Hsien-Yuan LaneShi-Heng WangChieh-Hsin LinPublished in: Psychiatry and clinical neurosciences (2022)
By enhancing two vital endogenous antioxidants, catalase and glutathione, sodium benzoate therapy improved cognition of patients with AD, with higher baseline catalase predicting better response. Supporting the oxidative stress theory, the results show promise for benzoate as a novel treatment for AD.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- oxidative stress
- phase iii
- phase ii
- study protocol
- mild cognitive impairment
- open label
- cognitive decline
- ischemia reperfusion injury
- white matter
- stem cells
- randomized controlled trial
- combination therapy
- bone marrow
- artificial intelligence
- mesenchymal stem cells
- induced apoptosis
- diabetic rats
- endoplasmic reticulum stress
- heat shock